<DOC>
	<DOCNO>NCT01561430</DOCNO>
	<brief_summary>The purpose Phase 2 study evaluate body handle drug drug 's effect body participant mild cognitive impairment ( MCI ) due Alzheimer 's Disease ( AD ) mild AD test positive amyloid plaque .</brief_summary>
	<brief_title>Study LY2886721 Mild Cognitive Impairment Due Alzheimer 's Disease Mild Alzheimer 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Cognition Disorders</mesh_term>
	<mesh_term>Mild Cognitive Impairment</mesh_term>
	<criteria>Meets criteria MCI due AD Mild AD All participant require undergo assessment via Mini Mental State Examination ( MMSE ) scale screen Participants MMSE score 20 26 , inclusive , may enrol provide meet criterion mild AD , follow : Participant meet National Institute Neurological Communicative Disorders Stroke/Alzheimer 's Disease Related Disorders Association ( NINCDS/ADRDA ) criteria probable AD ; Clinical Dementia Rating Scale ( CDR ) score 0.5 1 Positive scan presence amyloid beta Participants MMSE 27 30 , inclusive , may enrol participant MCI due AD provide meet follow criterion : Gradual progressive change memory function report participant caregiver period 6 month ; Free Cued Selective Reminding Test Immediate Recall ( FCSRTIR ) : free recall ≤22 total recall ≤46 ; Absence dementia ; Preservation functional independence ; Exclusion potential ( vascular , traumatic , medical ) cause cognitive decline , possible ; Positive scan presence amyloid beta Women must postmenopausal Men require use approve barrier method contraception partner pregnant , childbearing potential use approved contraceptive method Participant another drug device study Have history frontotemporal dementia , Lewy body disease , vascular dementia , Huntington 's disease Parkinson 's disease , progressive supranuclear palsy ( PSNP ) movement disorder Participants stable standard care ( acetylcholinesterase inhibitor , memantine ) initiate less two month prior entry less 4 week stable therapy . Note : Stable standard care allow Have serious infectious disease affect brain past 5 year Have serious repeat head injury Have significant retinal impairment disease Have stroke circulation problem affect current health Have seizure Have major depressive disorder stable dose medication . Participants longer meet Diagnostic Statistical Manual Mental Disorders , Fourth EditionText Revision ( DSMIV ) criteria major depression may include History schizophrenia , bipolar disorder severe mental illness . History alcohol drug abuse Have asthma , chronic obstructive pulmonary disease ( COPD ) breathe disease control medicine Have human immunodeficiency virus ( HIV ) syphilis Are take blood thinner</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>beta-secretase inhibitor</keyword>
</DOC>